These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 24317507)

  • 1. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
    Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S
    Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
    J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
    Kuwahara M; Arai Y; Takehara E; Sasaki Y; Yoshimine T; Kusaka K; Shikuma S; Akita W; Uchida S
    Clin Exp Nephrol; 2016 Aug; 20(4):585-594. PubMed ID: 26511877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin for the anaemia of chronic kidney disease.
    Palmer SC; Saglimbene V; Craig JC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009297. PubMed ID: 24683046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
    Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
    Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Chung EY; Palmer SC; Saglimbene VM; Craig JC; Tonelli M; Strippoli GF
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD010590. PubMed ID: 36791280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.
    Kuwahara M; Mandai S; Kasagi Y; Kusaka K; Tanaka T; Shikuma S; Akita W
    Clin Exp Nephrol; 2015 Aug; 19(4):598-605. PubMed ID: 25183365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study.
    Gobin J; Cernii A; McLean R; Finkelstein FO; Simon DB
    Clin Drug Investig; 2011; 31(2):113-20. PubMed ID: 21067252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
    Alsalimy N; Awaisu A
    Int J Clin Pharm; 2014 Dec; 36(6):1115-25. PubMed ID: 25288147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
    Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
    Biggar P; Ketteler M; Hennemann H; Dömling R
    Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
    Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.
    Choi P; Farouk M; Manamley N; Addison J
    Adv Ther; 2013 Nov; 30(11):1007-17. PubMed ID: 24173670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.